Direct-acting antiviral (DAA)

Direct-acting antivirals (DAAs) are medications used to treat hepatitis C by directly targeting the virus’s ability to replicate. They interfere with specific proteins essential for the virus's life cycle, effectively stopping it from multiplying and reducing the virus in your body. DAAs are highly effective, often curing hepatitis C in as few as 8 to 12 weeks with minimal side effects. This targeted approach has revolutionized hepatitis C treatment, making it safer, quicker, and more successful compared to older therapies.